About: William Jacot

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: William Jacot Goto Sponge NotDistinct Permalink

An Entity of Type : foaf:Person, within Data Space : data.idref.fr associated with source document(s)

Attributes	Values
type	Person
sameAs	Jacot, William Jacot, William Jacot, William Jacot, William
preferred label	Jacot, William
name	William Jacot
dbpedia-owl:citizenship	http://sws.geonames.org/3017382/
Language	http://lexvo.org/id/iso639-3/fra
isni:identifierValid	0000000004638328
Given name	William
familyName	Jacot
has biographical i...tion (Deprecated)	Praticien hospitalier à l'Institut de Recherche en Cancérologie de Montpellier (IRCM), U1194 INSERM, ICM et Université de Montpellier, depuis 2017
note	Titulaire d'un doctorat d'exercice en médecine (Montpellier, 2002)
gender	male
ORCID iD	0000-0001-7834-061X
is sameAs of	Jacot, William Jacot, William Jacot, William
is Thesis advisor of	http://www.sudoc.fr/127224556/id Les biomarqueurs de la déficience de la recombinaison homologue dans le cancer du sein triple négatif et le cancer de l’ovaire, implications pronostiques et thérapeutiques http://www.sudoc.fr/221734139/id Facteurs pronostiques et prédictifs dans le cancer du sein infiltrant http://www.sudoc.fr/109220226/id http://www.sudoc.fr/155842153/id http://www.sudoc.fr/176556656/id http://www.sudoc.fr/081616147/id http://www.sudoc.fr/134535278/id http://www.sudoc.fr/158180860/id http://www.sudoc.fr/223510386/id http://www.sudoc.fr/257375678/id http://www.sudoc.fr/260197742/id
is Praeses of	http://www.sudoc.fr/270227997/id http://www.sudoc.fr/270305874/id http://www.sudoc.fr/23434265X/id http://www.sudoc.fr/276432460/id
is Author of	http://www.sudoc.fr/177243414/id http://www.sudoc.fr/066771579/id http://www.sudoc.fr/114362866/id Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice. http://www.sudoc.fr/246962283/id Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort Machine Learning‐Assisted Evaluation of Circulating DNA Quantitative Analysis for Cancer Screening Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help? [HAS report on vitamin D measurement: don't go from an extreme situation to another as extreme situation] Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases? Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study Iron homeostasis and anemia markers in early breast cancer Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study https://serval.unil.ch/notice/serval:BIB_C092DDF58ABA#id ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations? Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program https://serval.unil.ch/notice/serval:BIB_B6A3B0A06A37#id Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer Diversity of Tumor-Infiltrating, γδ T-Cell Abundance in Solid Cancers Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2− pN0 early breast cancers Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the “APAD1” randomized controlled trial French law: what about a reasoned reimbursement of serum vitamin D assays? Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET) Clinical practice guidelines for BRCA1 and BRCA2 genetic testing Distinct oncogenes drive different genome and epigenome alterations in human mammary epithelial cells Oncoplastic Resection of Breast Cancers Located in the Lower-Inner or Lower-Outer Quadrant with the Modified McKissock Mammaplasty Technique CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers Anti-HER2 vaccines: new prospects for breast cancer therapy. Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers https://hal.archives-ouvertes.fr/hal-02869600#id Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study Clinicopathological and Treatment‐Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers https://serval.unil.ch/notice/serval:BIB_93F67FA9DFAF#id CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer Age and stage at diagnosis: a hospital series of 11 women with intellectual disability and breast carcinoma https://serval.unil.ch/notice/serval:BIB_75B4A28E2617#id Intérêt des marqueurs tumoraux et analyse des profils d'expression protéique sériques en oncologie thoracique Frequent expression of PD-L1 on circulating breast cancer cells [Vitamin D and breast cancer: physiopathology, biological and clinical implications] Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance database Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial Granulocyte- colony stimulating factor (G-CSF) use in clinical practice in patients receiving chemotherapy for breast cancer: The Opaline Study Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016

Faceted Search & Find service v1.13.91 as of Aug 16 2018

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software